Cagrilintide 10 mg
Also known as · NNC0174-0833 · CagriSema component
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked with GLP-1 receptor agonists in preclinical research.
Chemistry quick-facts
- Formula
- C176H274N48O53
- MW
- 3906.5 Da
- Length
- 32 aa
- Status
- Investigational. In Phase 3 development by Novo Nordisk (CagriSema — combined with semaglutide). Not approved standalone.
- Purity (HPLC)
- ≥ 98.5%
Mechanism of action
Agonism at calcitonin-family receptors (CT, AMY1, AMY2, AMY3). Slows gastric emptying, enhances satiety, modulates glucagon.
Research context
Cagrilintide is a once-weekly amylin analogue developed by Novo Nordisk. Native amylin is a 37-residue pancreatic hormone co-secreted with insulin; its receptor activation slows gastric emptying, increases satiety, and modulates post-prandial glucagon.
Cagrilintide combines amylin-/calcitonin-receptor agonism with a long-acting pharmacokinetic profile via C20 fatty-diacid conjugation.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Enebo LB, et al. (2021). Cagrilintide with semaglutide for weight management — Phase 1b. The Lancet.
- Lau DCW, et al. (2021). Once-weekly cagrilintide for weight management — Phase 2. The Lancet.
Active clinical trials
- NCT05567796Phase 3 · Ongoing
REDEFINE-1: CagriSema in obesity
- NCT05813925Phase 3 · Ongoing
REDEFINE-2: CagriSema in obesity with T2D
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
Can this be stacked with other peptides in a research protocol?+
Cagrilintide is most commonly paired with GLP-1 agonists in the published literature (the CagriSema programme). Each peptide is supplied separately; the decision to co-administer in a research protocol is the researcher's.
This page summarises the research literature on Cagrilintide 10 mg for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchRetatrutide 30 mg kit
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.
- ResearchRetatrutide 10 mg kit
Retatrutide 10 mg lyophilised vial kit — entry-point research presentation. Includes bac water, syringes, swabs.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.
- BiomarkerFasting insulin 12
Fasting insulin of 12 µIU/mL is above the optimal threshold most metabolic research uses (~8). What it indicates, why doctors miss it, and the research literature on early insulin resistance.
- BiomarkerHbA1c 5.7%
HbA1c at 5.7% is the formal threshold the ADA uses to define prediabetes — meaning your average blood glucose has been elevated over the past 2–3 months. What the number means and the research literature on intervention.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue